BioStock: AdjuTec takes on global antimicrobial resistance

AdjuTec Pharma is determined in its mission to address the escalating issue of antimicrobial resistance. Stemming from research at the University of Oslo, the company is now advancing towards creating adjuvant technologies to neutralise key bacterial resistance mechanisms. The company is currently heading towards phase I studies with its main candidate APC148.

Read the article at biostock.se:

AdjuTec takes on global antimicrobial resistance - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/